Results
A total of 32 randomized controlled trials (9,909 patients) met inclusion criteria. However, individual participant data were available from only 26 trials (6,708 patients), which were used in the individual participant data meta-analysis displayed in the Table. A sensitivity aggregate analysis was performed on all 32 trials, and in this analysis, mortality was not significantly different in the procalcitonin group compared with the control group.
Commentary
When a patient is facing a possible bacterial infection, it is often difficult for the provider to Individual patient data meta-analytic outcomes of procalcitonin-guided care versus standard care for acute respiratory infections. decide whether to initiate antibiotics and, if so, for how long. Although overuse contributes to bacterial resistance and can cause adverse effects such as anaphylaxis and diarrhea, underuse can lead to inadequate treatment and progression of disease. The challenge is to determine which patients with a diagnosis of respiratory illness are most likely to benefit.
In the presence of a bacterial infection, cytokines (tumor necrosis factor-a, interleukin-1-b, and interleukin-6) stimulate procalcitonin production and release from tissues. In contrast, during viral infections, the cytokine interferong blocks procalcitonin production. As a serum marker, procalcitonin increases with bacterial infections and decreases on recovery.
Procalcitonin has been studied in the ED to aid in the decisionmaking process for the initiation and duration of antibiotics, [1] [2] [3] and has been suggested to reduce antibiotic administration without increasing adverse events. 4 Acute respiratory infections are an ideal group in which to study the use of procalcitonin-driven protocols. They are heterogeneous in severity and cause, ranging from upper respiratory infections to pneumonia, and although primarily viral in origin they are a major source of antibiotic prescriptions. 5, 6 This systematic review and meta-analysis professes that procalcitoninguided acute respiratory infection treatment reduces mortality, antibiotic-related adverse effects, and duration of antibiotic exposure in ED patients.
However, this systematic review has substantial limitations. When the 14 ED randomized controlled trials included in the meta-analysis were evaluated, only 3 included patients that were not admitted. Many of the trials exclusively enrolled patients admitted to the hospital through the ED. This limits the generalizability to the majority of ED patients who present with acute respiratory infections and are expected to be discharged. Additionally, several authors were industry sponsored and half of the trials received funding from the biomarker industry. Because of conflicts of interest, it is stated at the end of the article that the lead author's relationships with industry was in violation of the Cochrane's Commercial Sponsorship Policy and that the author will step down as the lead author for future updates.
Procalcitonin-guided therapy may improve patient outcomes by reducing antibiotic exposure (less initiation, early discontinuation) and adverse effects. However, given the limited number of studies that enrolled subjects at ED presentation (rather than after admission), additional study is needed to determine the effectiveness of routine procalcitoninguided therapy for ED patients with acute respiratory infections who are treated as outpatients. 
